Bacillus coagulans GBI-30, 6086 limits the recurrence of Clostridium difficile-Induced colitis following vancomycin withdrawal in mice.
Bacillus coagulans GBI-30, 6086 limits the recurrence of Clostridium difficile-Induced colitis following vancomycin withdrawal in mice.
复制标题
DOI：
10.1186/1757-4749-4-13
复制
发表时间：
2012-10-22
期刊：
影响因子：
4.2
通讯作者：
Keller D
中科院分区：
文献类型：
--
作者：
Fitzpatrick LR;Small JS;Greene WH;Karpa KD;Farmer S;Keller D
最近，我们发现益生菌菌株凝结芽孢杆菌GBI-30，6086（GanedenBC 30）改善艰难梭菌（C. difficile）诱导的结肠炎（菲茨帕特里克等人，Gut Pathogens，2011）。我们的目标是确定BC 30是否也能预防C.艰难梭菌诱导的小鼠结肠炎，用万古霉素初始治疗后。在研究第0天至第5天期间，用抗生素处理小鼠。第6天，C.艰难梭菌菌株VPI 10463通过口胃管饲法以105 × 104 CFU给药以诱导结肠炎。在研究第6至10天，通过管饲法用万古霉素（50 mg/kg）（vanco）或溶媒（盐水）处理小鼠。在第10至16天，通过管饲法向小鼠给予盐水媒介物或BC 30（每天2 X IO 9 CFU）。监测小鼠的死亡率、体重减轻和腹泻。在研究第14、16和17天，收集粪便和结肠用于分析结肠炎的其他参数。溶媒/艰难梭菌/Vanco小鼠的平均粪便稠度评分从0.4（第10天）增加至1.1 - 1.4（第14 - 17天），表明结肠炎复发。第13天至第17天，万古霉素/BC 30小鼠的粪便稠度评分显着低于（p< 0.05）万古霉素/溶剂动物队列。在第17天，88.9%的用BC 30处理的小鼠具有正常粪便，而该值在用媒介物处理的情况下为0%（p值= 0.0004）。结肠髓过氧化物酶（单位/2cm结肠）从4.3 ± 0.7（媒介物/艰难梭菌/Vanco）显著（p < 0.05）降低至2.6 ± 0.2（BC 30/C. Difficle/Vanco）。结肠组织学评分和结肠中角质细胞衍生的趋化因子水平在BC 30处理的小鼠中也较低。在BC 30处理的小鼠中，有证据表明，在用万古霉素初始处理动物后，粪便稠度更好，结肠炎的生化和组织学指标也有所改善。BC 30限制了小鼠中停用万古霉素后CD诱导的结肠炎的复发。
Recently, we found that the probiotic strain Bacillus coagulans GBI-30, 6086 (GanedenBC30) improved indices of Clostridium difficile (C. difficile)-induced colitis in mice (Fitzpatrick et al., Gut Pathogens, 2011). Our goal was to determine if BC30 could also prevent the recurrence of C. difficile-induced colitis in mice, following initial treatment with vancomycin. During study days 0 through 5, mice were treated with antibiotics. On day 6, the C. difficile strain VPI 10463 was given by oro-gastric gavage at ≈ 5x104 CFU to induce colitis. Mice were treated on study days 6 to 10 with vancomycin (50 mg/kg) (vanco) or vehicle (saline) by gavage. On days 10 to16, mice were dosed by gavage with saline vehicle or BC30 (2 x 109 CFU per day). Mice were monitored for mortality, weight loss and diarrhea. On study days 14, 16 and 17, stools and colons were collected for analyzing other parameters of colitis. The mean stool consistency score in Vehicle/C.difficile/Vanco mice increased from 0.4 (day 10) to a range of 1.1 to 1.4 (days 14 to 17), indicating the recurrence of colitis. On days 13 through 17, the stool consistency scores for the vancomycin/BC30 mice were significantly lower (p< 0.05) than for the vancomycin/vehicle cohort of animals. On day 17, 88.9% of mice treated with BC30 had normal stools, while this value was 0% with vehicle treatment (p value = 0.0004). Colonic myeloperoxidase (Units/2 cm colon) was significantly (p < 0.05) reduced from 4.3 ± 0.7 (Vehicle/C.difficile/Vanco) to 2.6 ± 0.2 (BC30/C. Difficle/Vanco). The colonic histology score and Keratinocyte derived-chemokine level in the colon were also lower in BC30 treated mice. In BC30-treated mice, there was evidence of better stool consistency, as well as improved biochemical and histological indices of colitis, following initial treatment of animals with vancomycin. BC30 limited the recurrence of CD-induced colitis following vancomycin withdrawal in mice.
登录
查看更多内容
影响因子：
12.2
作者：
Reeves, Angela E.;Theriot, Casey M.;Young, Vincent B.
通讯作者：
Young, Vincent B.
影响因子：
158.5
作者：
McDonald, LC;Killgore, GE;Gerding, DN
通讯作者：
Gerding, DN
影响因子：
3.1
作者：
Sun, Xingmin;Wang, Haiying;Feng, Hanping
通讯作者：
Feng, Hanping
影响因子：
4.2
作者：
Fitzpatrick, Leo R.;Small, Jeffrey S.;Keller, David
通讯作者：
Keller, David
影响因子：
14.6
作者：
Pépin, J;Valiquette, L;Chouinard, D
通讯作者：
Chouinard, D